No Data
Hong Kong stock movement | REMEGEN (09995) once rose by over 12% as the results of the first-line treatment for gastric cancer with Widi Xituzumab were selected for the 2025 ASCO oral presentation.
REMEGEN (09995) once rose more than 12%, as of the time of writing, it has risen 7.79%, priced at 38.05 Hong Kong dollars, with a trading volume of 0.298 billion Hong Kong dollars.
Trending Industry Today: INNOCARE Leads Gains In Biotechnology Stocks
REMEGEN (09995.HK) will release its Earnings Reports on April 28.
$REMEGEN (09995.HK) will release its Earnings Reports on April 28. Investors should pay attention. How was the previous performance? In Q1 2024, the revenue was 0.33 billion yuan, net income was -0.349 billion yuan, and EPS was -0.65 yuan. Futubull reminder: 1. There are no strict regulations on the accounting year division for listed companies in Hong Kong and the United States; it is completely decided by the companies themselves. Therefore, each earnings report period can serve as the year-end for the company's annual report, rather than following the natural calendar as the fiscal year. 2. Generally, companies will hold an earnings report meeting on or around the date of the earnings report release, with the company management.
REMEGEN (688331.SH): There are no plans to develop CDMO Business.
On April 18, Gelonghui reported that REMEGEN (688331.SH) stated on the interactive platform that the company currently has no plans to engage in CDMO Business. Regarding the negotiations for international BD, the company will strictly adhere to relevant laws and regulations and timely fulfill its information disclosure obligations based on the progress of the negotiations. Please refer to the information disclosed on the company's official platforms for specifics.
Trending Industry Today: SKB BIO-B Leads Losses In Biotechnology Stocks
Hong Kong stock movement | REMEGEN (09995) surged over 7% as the gMGIII phase data for TaiTasiP is excellent, and first-quarter performance will be disclosed at the end of the month.
REMEGEN (09995) rose over 7%, with a cumulative increase of over 30% in stock price this month. As of the time of publication, it increased by 7.45%, priced at 32.45 Hong Kong dollars, with a transaction amount of 0.116 billion Hong Kong dollars.
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
